PMID- 30834030
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220408
IS  - 1918-2805 (Print)
IS  - 1918-2813 (Electronic)
IS  - 1918-2805 (Linking)
VI  - 12
IP  - 1
DP  - 2019 Feb
TI  - Sorafenib-Related Adverse Events in Predicting the Early Radiologic Responses of 
      Hepatocellular Carcinoma.
PG  - 16-20
LID - 10.14740/gr1109 [doi]
AB  - BACKGROUND: Hepatocellular carcinoma (HCC) has a poor prognosis with low 
      chemotherapeutic efficiency to medications except to sorafenib. Previous studies 
      showed that adverse events (AEs) of sorafenib can predict therapy efficacy to 
      HCC. The aim of the study is to evaluate the early efficacy and AEs of sorafenib 
      therapy. METHODS: The database of HCC patients receiving sorafenib at Taichung 
      Veterans General Hospital during the period from June 2012 to October 2016 was 
      analyzed. All HCC cases were Barcelona Clinic Liver Cancer (BCLC) classification 
      stage C. The early efficacy of sorafenib was classified according to the mRECIST 
      criteria as either partial response (PR), stable disease (SD) or progressive 
      disease (PD). Responses were recorded within 6 weeks after the start of sorafenib 
      treatment. AEs were defined as the appearance of hand-foot skin reaction (HFSR), 
      hypertension (HTN) and diarrhea. Exclusion criteria were poor performance status, 
      poor drug compliance, discontinued follow-up or mortality occurring within 1 day 
      after medication. RESULTS: From a total of 222 subjects, eight cases (3.6%) were 
      classified as PR, 82 cases (36.9%) SD, and 132 cases (59.5%) PD. The PR group had 
      the highest ratio of HFSR (62.4%) and hypertension (37.5%). Pooling cases of PR 
      and SD together, the presence of HFSR adjusted odd ratio (aOR) 2.80, 95% 
      confidence interval (CI) 1.52 - 5.16) and diarrhea (aOR 3.42, 95% CI 1.67 - 7.01) 
      were good predictors of favorable responses to sorafenib therapy. CONCLUSIONS: 
      HFSR and diarrhea are good predictors of early therapy efficacy to the sorafenib 
      treatment.
FAU - Lee, Shou-Wu
AU  - Lee SW
AD  - Division of Gastroenterology, Department of Internal Medicine, Taichung Veterans 
      General Hospital, Taichung, Taiwan.
AD  - Department of Internal Medicine, Chung Shan Medical University, Taichung, Taiwan.
FAU - Lee, Teng-Yu
AU  - Lee TY
AD  - Division of Gastroenterology, Department of Internal Medicine, Taichung Veterans 
      General Hospital, Taichung, Taiwan.
AD  - Department of Internal Medicine, Chung Shan Medical University, Taichung, Taiwan.
FAU - Yang, Sheng-Shun
AU  - Yang SS
AD  - Division of Gastroenterology, Department of Internal Medicine, Taichung Veterans 
      General Hospital, Taichung, Taiwan.
AD  - Department of Internal Medicine, Yang-Ming University, Taipei, Taiwan.
FAU - Tong, Chun-Fang
AU  - Tong CF
AD  - Division of Gastroenterology, Department of Internal Medicine, Taichung Veterans 
      General Hospital, Taichung, Taiwan.
FAU - Yeh, Hong-Zen
AU  - Yeh HZ
AD  - Division of Gastroenterology, Department of Internal Medicine, Taichung Veterans 
      General Hospital, Taichung, Taiwan.
AD  - Department of Internal Medicine, Yang-Ming University, Taipei, Taiwan.
FAU - Chang, Chi-Sen
AU  - Chang CS
AD  - Division of Gastroenterology, Department of Internal Medicine, Taichung Veterans 
      General Hospital, Taichung, Taiwan.
AD  - Department of Internal Medicine, Chung Shan Medical University, Taichung, Taiwan.
LA  - eng
PT  - Journal Article
DEP - 20190226
PL  - Canada
TA  - Gastroenterology Res
JT  - Gastroenterology research
JID - 101519422
PMC - PMC6396795
OTO - NOTNLM
OT  - Hand-foot skin reaction
OT  - Hepatocellular carcinoma
OT  - Sorafenib
EDAT- 2019/03/06 06:00
MHDA- 2019/03/06 06:01
PMCR- 2019/02/01
CRDT- 2019/03/06 06:00
PHST- 2018/11/02 00:00 [received]
PHST- 2018/12/10 00:00 [accepted]
PHST- 2019/03/06 06:00 [entrez]
PHST- 2019/03/06 06:00 [pubmed]
PHST- 2019/03/06 06:01 [medline]
PHST- 2019/02/01 00:00 [pmc-release]
AID - 10.14740/gr1109 [doi]
PST - ppublish
SO  - Gastroenterology Res. 2019 Feb;12(1):16-20. doi: 10.14740/gr1109. Epub 2019 Feb 
      26.